Form 4: Coya Therapeutics Director Acquires Stock Options

Director Wilbur L. Ross Jr. of Coya Therapeutics acquired 5,000 stock options on January 1, 2025, which vest on the first anniversary of the grant date.

Summary

• Wilbur L. Ross Jr., a director at Coya Therapeutics, acquired 5,000 stock options on January 1, 2025.
• These options have an exercise price of $5.73 per share.
• The options will vest 100% on January 1, 2026, the first anniversary of the grant date, subject to continuous service.
• The options expire on January 1, 2035.
• The underlying security is common stock of Coya Therapeutics with a par value of $0.0001 per share.

Sentiment

Score: 7

Explanation: The document reflects a standard transaction, which is generally positive as it aligns director interests with shareholders. There is no indication of any negative sentiment.

Positives

• The acquisition of stock options by a director can be seen as a positive sign of confidence in the company's future.

Industry Context

This is a standard transaction for a director of a publicly traded company, often used as part of compensation packages to align interests with shareholders.

Comparison to Industry Standards

• Stock option grants to directors are a common practice across the biotechnology industry.
• The vesting schedule of one year is also typical for such grants.
• The exercise price is likely based on the market value of the stock at the time of the grant.

Stakeholder Impact

• The stock option grant could positively impact shareholder sentiment by aligning director interests with the company's performance.

Key Dates

Keywords

stock options, director, Coya Therapeutics, insider trading, equity, vesting